TB Alliance and Lupin Announce Collaboration to Advance and Commercialize Telacebec for Multiple Neglected Diseases

30 January 2026

TB Alliance press release

TB Alliance, a nonprofit drug developer, and Lupin Limited, a global pharma major, announced a global collaboration to advance the clinical development and commercialization of the investigational drug telacebec (formerly known as Q203) for the treatment of TB, leprosy, and Buruli ulcer.

Under the collaboration, TB Alliance and Lupin will work together to support the continued clinical development of telacebec and prepare for its potential future commercialization, with the shared goal of improving treatment options for people affected by these neglected diseases. TB Alliance will continue to lead development activities, while Lupin will bring its global manufacturing, regulatory, and supply expertise to help ensure broad access to telacebec.

Read the full press release here.

Source: TB Alliance